Redeye finetunes its estimates following the Q4 2023 report from Respiratorius.
Redeye updates on EG7 post Q4-results which came in lower than expected, driven mainly by Big Blue B...
This year did not start off as well as last year, which could make it hard for Scanfil to improve it...
Sales and orders grew nicely in Q4, but comps are getting tougher We stick to ~15% annual growth ahe...
4% sales beat vs cons but weaker gross margin put adj.
Sweden still affected by cautious hiring policy Positive development in UK Normalisation before next...
Redeye is encouraged about the preliminary Q4 2023 topline result from TH1NG, which exceeds our expe...
Redeye briefly comments on Curasight’s rights issue.
Scandpower excels through licence sales Higher sick leave in Decommissioning Minor revisions with '2...
Q4 report due on Friday 23 February '24e-'25e EBITA down 2-1%, UK raised but Germany lowered Share +...
Försäljningstrenden verkar ha vänt… Med valutajusterad tillväxt på +10% både y/y och sekventiellt ve...
Återupptagen bevakning med motiverat värde 2,5-3,3 Vi återupptar bevakning av Midsummer med ett nytt...
Solteq reports Q4 on February 15th. Our key points of interest relate to the market and growth outlo...
Endomines will release its H2 2023 figures on February 15th.
Redeye saw a report that came in as expected regarding the results.
Q4 EBITDA of USD 21.5m, in line with ABGSCe Estimates down on lower production assumptions Fair valu...
Redeye comments on EG7’s Q4-results which were weaker than expected, mainly owing to a faster-than-e...
Redeye comments that Dignitana has received market approval for DigniCap Delta in Japan.
Investors House reported Q4 2023 revenue of EUR 1.8m, the same as our estimate, while adjusted EBIT ...
Viscaria environmental permit hearing currently in progress.
.jpg)
